1
|
Kim KM, D'Elia AM, Rodell CB. Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease. Adv Drug Deliv Rev 2024; 212:115395. [PMID: 39004347 DOI: 10.1016/j.addr.2024.115395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 06/23/2024] [Accepted: 07/08/2024] [Indexed: 07/16/2024]
Abstract
A robust adaptive immune response is essential for combatting pathogens. In the wrong context such as due to genetic and environmental factors, however, the same mechanisms crucial for self-preservation can lead to a loss of self-tolerance. Resulting autoimmunity manifests in the development of a host of organ-specific or systemic autoimmune diseases, hallmarked by aberrant immune responses and tissue damage. The prevalence of autoimmune diseases is on the rise, medical management of which focuses primarily on pharmacological immunosuppression that places patients at a risk of side effects, including opportunistic infections and tumorigenesis. Biomaterial-based drug delivery systems confer many opportunities to address challenges associated with conventional disease management. Hydrogels, in particular, can protect encapsulated cargo (drug or cell therapeutics) from the host environment, afford their presentation in a controlled manner, and can be tailored to respond to disease conditions or support treatment via multiplexed functionality. Moreover, localized delivery to affected sites by these approaches has the potential to concentrate drug action at the site, reduce off-target exposure, and enhance patient compliance by reducing the need for frequent administration. Despite their many benefits for the management of autoimmune disease, such biomaterial-based approaches focus largely on the downstream effects of hypersensitivity mechanisms and have a limited capacity to eradicate the disease. In contrast, direct targeting of mechanisms of hypersensitivity reactions uniquely enables prophylaxis or the arrest of disease progression by mitigating the basis of autoimmunity. One promising approach is to induce self-antigen-specific tolerance, which specifically subdues damaging autoreactivity while otherwise retaining the normal immune responses. In this review, we will discuss hydrogel-based systems for the treatment of autoimmune disease, with a focus on those that target hypersensitivity mechanisms head-on. As the field continues to advance, it will expand the range of therapeutic choices for people coping with autoimmune diseases, providing fresh prospects for better clinical outcomes and improved quality of life.
Collapse
Affiliation(s)
- Kenneth M Kim
- Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA.
| | - Arielle M D'Elia
- School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA.
| | - Christopher B Rodell
- Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA; School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA.
| |
Collapse
|
2
|
Dvořáková M, Svobodová L, Rucki M, Ševčík V, Hošíková B, Chrz J, Bendová H, Kejlová K, Očadlíková D, Malý M, Kolářová H, Mannerström M, Kanďárová H, Jírová D. The Safety Assessment of Cosmetic Perfumes by Using In Chemico and In Vitro Methods in Combination with GC-MS/MS Analysis. Altern Lab Anim 2023; 51:224-248. [PMID: 37377062 DOI: 10.1177/02611929231184635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/29/2023]
Abstract
Animal testing has been prohibited for the safety assessment of cosmetic ingredients or finished products. Thus, alternative non-animal methods, followed by confirmatory clinical studies on human volunteers, should be used as the sole legally acceptable approach within the EU. The safety assessment of cosmetic products requires the involvement of multiple scientific disciplines, including analytical chemistry and biomedicine, as well as in chemico, in vitro and in silico toxicology. Recent data suggest that fragrance components may exert multiple adverse biological effects, e.g. cytotoxicity, skin sensitisation, (photo)genotoxicity, mutagenicity, reprotoxicity and endocrine disruption. Therefore, a pilot study was conducted with selected samples of fragrance-based products, such as deodorant, eau de toilette and eau de parfum, with the aim of integrating results from a number of alternative non-animal methods suitable for the detection of the following toxicological endpoints: cytotoxicity (with 3T3 Balb/c fibroblasts); skin sensitisation potential (in chemico method, DPRA); skin sensitisation potential (LuSens in vitro method, based on human keratinocytes); genotoxicity potential (in vitro Comet assay with 3T3 Balb/c cells); and endocrine disruption (in vitro YES/YAS assay). The presence of twenty-four specific known allergens in the products was determined by using GC-MS/MS. The strategies for estimation of the NOAEL of a mixture of allergens, which were proposed by the Scientific Committee on Consumer Products in their 'Opinion on Tea tree oil' document and by the Norwegian Food Safety Authority in their 'Risk Profile of Tea tree oil' report, were used as models for the NOAEL estimation of the mixtures of allergens that were identified in the individual samples tested in this study.
Collapse
Affiliation(s)
- Markéta Dvořáková
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
- Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - Lada Svobodová
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
- Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
| | - Marian Rucki
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
| | - Václav Ševčík
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
- Department of Analytical Chemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic
| | - Barbora Hošíková
- Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
| | - Jan Chrz
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
- Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
| | - Hana Bendová
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
| | - Kristina Kejlová
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
| | - Danuše Očadlíková
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
| | - Marek Malý
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
| | - Hana Kolářová
- Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
| | - Marika Mannerström
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
| | - Helena Kanďárová
- Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, Bratislava, Slovakia
| | - Dagmar Jírová
- Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic
| |
Collapse
|
3
|
Montero Pérez O, Martinez Benavides J, González Fernandez T, Guerra Prio S, Romero Domínguez R, Mesía Nin R, Clopés Estela A. Is ranitidine necessary as premedication for regimens containing paclitaxel? A non-inferiority study. Expert Rev Clin Pharmacol 2023; 16:877-883. [PMID: 37477611 DOI: 10.1080/17512433.2023.2238596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Accepted: 07/16/2023] [Indexed: 07/22/2023]
Abstract
BACKGROUND Histamine type-2-receptor antagonist drugs (H2-antagonists) have been used as standard treatment to prevent hypersensitivity reactions (HRs) in paclitaxel-containing regimens, however, their use has been strongly questioned. Ranitidine has been the most widely used H2-antagonist. Therefore, especially after its withdrawal from the market, the objective of this study is to determine the impact of its elimination from premedication on HR incidence. METHODS A cohort, multicenter, observational, prospective, and non-inferiority study, including paclitaxel-naïve cancer patients, designed to determine the incidence of HRs of any grade associated with paclitaxel administration and analyze non-inferiority against the incidence estimated in the literature (20%), with 5% as the maximum difference (Δ). Patients with a solid neoplasm of any type/stage, who initiated treatment with paclitaxel without H2-antagonists in the premedication regimen were enrolled. RESULTS A total of 441 patients were included, of whom 50 presented 54 HRs of any grade. The cumulative incidence was 11.3% (95%CI 8.5-14.7), thus fulfilling the hypothesis of non-inferiority. Of the overall HRs detected, 15 were grade ≥ 3 with a cumulative incidence of 3.4% (95%CI 1.9-5.5). CONCLUSIONS This study demonstrates that the elimination of ranitidine from paclitaxel premedication schedules is non-inferior in the development of HRs of any grade compared to the administration of H2-antagonists.
Collapse
Affiliation(s)
| | | | | | | | | | - Ricard Mesía Nin
- Medical Oncology Department, Catalan Institute of Oncology, Badalona. B-ARGO Group, IGTP, Badalona, Spain
| | - Ana Clopés Estela
- Pharmacy Department, Catalan Institute of Oncology, Barcelona, Spain
| |
Collapse
|